Antimicrobial resistance has continued to undermine many popular anti-Helicobacter pylori therapies. Antibiotic resistance to commonly used anti-H. pylori drugs in China has increased markedly, making China an ideal site to identify regimens that remain effective despite widespread antimicrobial resistance. Bismuth is one of the few antimicrobials to which resistance does not develop. Factors contributing to H. pylori treatment success include host factors (e.g. genetic differences in the metabolism of the drugs used), bacterial factors (e.g. susceptibility), and details of the regimen (e.g. doses, dosing interval, dosing in relation to meals, formulation, etc.). We reviewed the recent experience in China with bismuth-containing quadruple therapies. The experience consists of 16 studies with 25 arms involving 1971 patients to identify successful regimens (defined as reliably obtaining 90% or greater eradication per protocol) deserving further study. Despite high rates of resistance to commonly used antimicrobials, several regimens could achieve high success. These were characteristically 14-day regimens containing a proton pump inhibitor and either tetracycline and metronidazole or furazolidone and amoxicillin. We propose approaches for further development including for optimization and simplification related to convenience and side effects (e.g. twice rather than three or four times daily or administration at the noon and evening meal instead of at breakfast and evening) while maintaining effectiveness of at least 90%. Studies in China identified regimens that were highly effective despite the high prevalence of resistance to metronidazole, fluoroquinolones, and macrolides. Multicenter randomized studies will be required to confirm which is the best.
Introduction
Gastric inflammation has been known to be associated with peptic ulcers and with gastric cancer for at least 100 years [1] [2] [3] [4] [5] . Although an infectious etiology of chronic gastritis was considered in the first half of the 20th century, proof was not obtained until the 1980s following the culture of Helicobacter pylori by Marshall et al. [6] . The fact that chronic gastritis had an infectious cause suggested that cure of the infection would likely cure or prevent peptic ulcer disease and gastric cancer as these diseases were known to be strongly associated with gastritis. The discovery of H. pylori was rapidly followed by numerous studies seeking to identify an effective and reliably curative therapy (reviewed in Borsch and Graham [7] ). Progress has been slow and advances have often been temporary because of increasing antimicrobial resistance.
An optimal anti-H. pylori regimen is defined as one that reliably produces a cure rate of at least 90 (preferably Z 95%) for treatment of susceptible organisms. Few if any anti-H. pylori treatment regimens have been optimized and the general lack of susceptibility data has forced clinicians to select therapy empirically. Because of the lack of susceptibility data, an optimal therapy might be defined as one that reliable achieves high cure rates (e.g. Z 90%) irrespective of the presence of antimicrobial resistance. The first reliably effective antimicrobial regimen was a multidrug combination consisting of bismuth subcitrate, metronidazole, and tetracycline (BMT) [8, 9] . It was soon recognized that the effectiveness of BMT was reduced in the presence of metronidazole resistance and further studies showed that its effectiveness could be restored at least partially by the addition of a proton pump inhibitor (PPI) along with using higher doses of metronidazole and extending the duration [10] [11] [12] [13] .
Bismuth-containing quadruple therapies have been used widely in H. pylori therapy with many permutations of doses and durations and with variable results [14, 15] . The early observations that antimicrobial doses and treatment duration were critical determinants of outcome have been confirmed repeatedly (e.g. 7-day bismuth quadruple regimens typically produce unacceptably low cure rates in areas where metronidazole resistance is 40% or greater) [13, 14, 16, 17] .
It is unknown whether one bismuth preparation or formulation is superior to others. All commercially available bismuth preparations have anti-H. pylori activity [18] but direct comparisons between bismuth salts and formulations are lacking. Bismuth potassium citrate, colloidal bismuth pectin, and colloidal bismuth subcitrate are available in China, where they have been used widely for the treatment of diarrhea or dyspepsia. Bismuth salts are topical antimicrobials and while rarely curative as monotherapy, markedly reduce the bacterial load of H. pylori and apparently have synergistic effects with other antibiotics [19] . Importantly, resistance to bismuth does not develop, making bismuth a preferred antimicrobial agent for the treatment of H. pylori infections in areas where resistance to other antimicrobials is common and retreatment may be needed.
Although bismuth salts have long been used as antiulcer agents, bismuth preparations and formulations differ in their antiulcer properties. For example, colloidal bismuth subcitrate forms complexes with mucus and can coat ulcer craters. This has been suggested to protect the mucosa and ulcer base from acid-peptic attack while increasing mucosal prostaglandin synthesis and bicarbonate secretion [20] . The colloidal form of bismuth subcitrate has been shown to be effective for preventing ulceration in Shay rats, whereas noncolloidal bismuth subcitrate was not [21] , and studies of experimental ulcers have suggested that the ulcer-healing properties of colloidal bismuth subcitrate are not shared with bismuth subsalicylate, bismuth subcarbonate, or bismuth subnitrate [20, 22] . To the best of our knowledge, there are no comparative studies on colloidal bismuth pectin. For the treatment of H. pylori, bismuth is primarily used as a topical antimicrobial and it is unclear whether its antiulcer properties are also important. Because the preparations appear similar in terms of H. pylori eradication, one would expect not.
Chinese H. pylori treatment guidelines recommend bismuth-containing quadruple therapies for both firstline and rescue treatments for H. pylori infection. Here, we summarize the effectiveness of bismuth-containing quadruple regimens that have been tested in China and, where possible, compare the results to local H. pylori resistance patterns.
Methods
This is a narrative review of the bismuth-containing quadruple therapy in China. Eligible articles were identified by a search of electronic databases. We included all randomized trials using bismuth-containing quadruple regimens for the treatment of H. pylori infection in China from 2006 to 2013. The experience consisted of 16 studies with 25 arms involving 1971 patients. The definition of a successful regimen was based on the treatment success per protocol using the grading system (Z 95% = excellent, Z 90% = good, 85-89% = borderline acceptable, r 85% = unacceptable).
The goal of this approach was to identify regimens that have the potential for successful clinical use (i.e. those that should be studied further in different populations, in relation to antimicrobial resistance) and are also candidates for optimization in terms of doses, frequency of administration, costs, and side effects while maintaining effectiveness as a measure by cure rates of at least 90%. For exploratory studies, the primary outcome is generally expressed per protocol (PP), which controls for compliance and other variables and thus provides an indication of the potential maximum success of regimen in clinical practice. In addition, the data should also be expressed as intention to treat (ITT), which includes all patients randomized to therapy and who received at least one dose of medicine: those lost to follow-up are typically scored as treatment failures. ITT provides an estimates of a regimen's actual success in clinical practice and is the standard for randomized multicenter trials, whereas PP is the most useful for exploratory studies to develop new regimens.
Helicobacter pylori resistance to antibiotics in China
Resistance to antibiotics is the major cause of H. pylori treatment failure with otherwise effective antimicrobial therapy. Antimicrobial resistance in H. pylori has increased rapidly in China in concert with an increase in antibiotic consumption. For example, a multicenter study carried out between 2008 and 2010 in four main cities in China showed resistance rates of 69.7% for metronidazole, 37.8% for clarithromycin, 36.4% for levofloxacin, 38.2% for moxifloxacin, 4.9% for amoxicillin, and 2.3% for tetracycline [23] . In Shanghai, Sun et al. [24] investigated antibiotic resistance among H. pylori in 2000, 2005, and 2009. During that time, clarithromycin resistance increased from 8.6 to 20.7%, levofloxacin resistance increased from 10.3 to 32.5%, whereas resistance to metronidazole remained high but stable between 40 and 50%. All strains tested in that study were susceptible to amoxicillin and furazolidone and only one strain (isolated in 2005) was resistant to tetracycline [24] . Gao et al. [25] also showed that over the last 10 years, there has been an increase in clarithromycin resistance from 14.8 to 65.4%, metronidazole resistance from 38.9 to 78.8%, and fluoroquinolone resistance from 27.1 to 63.5% in Beijing. In Beijing, as in Shanghai, amoxicillin resistance (0.3%) and tetracycline resistance (1.2%) remain rare [25] . As expected from these data, treatment success with standard triple therapy, 10-day sequential therapy, or levofloxacin-containing triple therapy was all unsatisfactory. For example, a nationwide, multicenter clinical study showed the PP eradication rate of standard 10-day sequential therapy was only 75.2% (185/246) [26] . A study from Beijing in 2010 compared 7-day standard triple therapy and 7-day levofloxacin-containing triple therapy and reported ITT cure rates of only 74.5% (111/ 149) and 78.2% (111/142) for 7-day standard triple therapy and 82.4% (122/148) and 83.0% (122/147) for levofloxacin-containing triple therapy [27] . These generally poor results suggest that clarithromycin and fluoroquinolone-containing anti-H. pylori triple therapy regimens should be abandoned as empiric therapies in China and should only be used with previous susceptibility testing confirming the presence of susceptible strains or in low-resistance areas. Given the generally low prevalence of resistance to tetracycline and the ability to partially overcome the effects of resistance by increasing the doses and duration of bismuth quadruple therapy, bismuthcontaining regimens would appear to be especially useful in China.
Bismuth-containing quadruple regimens Western experiences
In western countries, the best results with bismuth quadruple therapy in areas with moderate to high rates of metronidazole resistance (e.g. Z 40%) are obtained with a 10-14-day (14 days being preferred) regimen provided four times a day [13, 28, 29] . However, several studies from Sardinia, Italy, have suggested that twice a day dosing (administered with lunch and the evening meals) may be as effective while also reducing the total amount of antibiotics given to one-half [30] [31] [32] . In early western studies, the replacement of tetracycline by amoxicillin did not prove to be as effective as bismuth tetracyclinecontaining regimens [15] , but may have an advantage in regions where tetracycline resistance is an issue. Substitution of clarithromycin for metronidazole proved effective in areas where clarithromycin resistance was low but one would expect its effectiveness to be limited to those areas [33] . Substitution of doxycycline for tetracycline also provided a less effective outcome and is not recommended by western investigators [34, 35] .
Bismuth-containing quadruple therapy in China (bismuth, tetracycline, metronidazole, proton pump inhibitor)
There have been a number of studies of bismuthcontaining anti-H. pylori therapy in China (Table 1) . Overall, the results with traditional bismuth quadruple therapy in China are consistent with western results in regions where metronidazole resistance is greater than 40% (i.e. the outcome is relatively poor unless full dose and duration therapy is used). For example, a 7-day study in Shanghai with colloidal bismuth subcitrate, 1.5 g tetracycline (750 mg twice daily), and 1200 mg metronidazole provided low cure rates (79.1% ITT, 82.9% PP). However, prolonging the duration to 10 days was associated with an increase in the cure rate (to 88.9% ITT and 90.9-91.6% PP) [17, 37] . There have been two studies with 10-day therapy: one with 220 mg bismuth potassium citrate twice daily, 2250 mg tetracycline and 1500 mg metronidazole that produced 76.7% ITT and 83.3% PP [36] , and one study with 220 mg bismuth potassium citrate but only twice daily, a very high dose of tetracycline (3 g) and a low dose of metronidazole (800 mg), which also yielded poor results (59.5% ITT, 64.1% PP) [38] . However, a recent study of a 2-week bismuth-containing quadruple therapy containing a PPI and bismuth subcitrate 220 mg twice daily, 500 mg of tetracycline, and 400 mg of metronidazole both four times a day, achieved cure rates of 93.1% [95% confidence interval (CI), 88.1-98.0%] PP and 87.9% (95% CI, 81.7-94.0%) ITT [39] . In that study, cure rates of B90% were achieved despite almost universal metronidazole resistance (Table 1) [39] . These results suggest that a potentially effective regimen has been identified and, interestingly, it is similar or identical to the regimen proven to be successful in the West [29] .
Bismuth-furazolidone-containing quadruple therapies
Furazolidone is a monoamine oxidase inhibitor with broad antibacterial activity based on interference with bacterial enzymes. Furazolidone was used to treat peptic ulcer disease in China for many years before H. pylori was discovered [43] . The consensus reports in China of 2005, 2007 , and 2012 all recommend furazolidone for H. pylori treatment [44] [45] [46] .
A 2009 study compared the cure rates of 1-and 2-week furazolidone (100 mg twice daily) and 2-week higher dose furazolidone (100 mg three times daily) quadruple therapy. They found that extending the antibiotic course to 2 weeks and increasing the dose of furazolidone improved the eradication rate [41] . Four treatment arms using furazolidone and amoxicillin have been reported including a nationwide multicenter, randomized, controlled trial investigating the efficacy of furazolidonecontaining triple and quadruple therapies for H. pylori eradication (Table 2) [39] [40] [41] [42] . As there is almost no amoxicillin and furazolidone resistance reported in China, one would expect good outcomes. The outcomes (ITT) of 10-or 14-day regimens show eradication rates of at least 85% [42] . A large, single-center, randomized study that included 424 participants reported that cure rates after 2 weeks of high-dose amoxicillin (1 g three times daily) and furazolidone (0.1 g three times daily) were as high as 95.2% (95% CI, 91.1-99.3%) PP and 99.0% (95% CI, 97.0-100%) ITT. In that comparative study, eradication rates with furazolidone-containing regimens were significantly greater than with nonfurazolidone regimens (Table 1) [39] .
The fact that clarithromycin resistance is high where the study was carried out (i.e. 18% in Shanghai) suggested that the combination of bismuth and amoxicillin alone might be sufficient in that population and a small pilot study testing this hypothesis would be of interest.
A randomized, open-label trial in four cities (eight sites) in China was conducted to compare the 10-day clarithromycin, amoxicillin, PPI quadruple therapies with bismuth and ecabet sodium and, although antibiotic resistance rates were not assessed, the eradication rates were higher in the low clarithromycin resistance area (e.g. Shanghai, 81.3% ITT and 89.7% PP) than in the high resistance area (e.g. Xi'an, 50.0% ITT and 53.6% PP) [50] . Overall, the results are consistent with the notion that clarithromycin resistance is now so common and widespread in China that its use as an empiric choice is limited (Table 3) .
Miscellaneous bismuth-containing quadruple regimens
Finally, there have been a number of other combinations of bismuth, a quinolone, and a third drug (amoxicillin or furazolidone) (Table 4) [40, 41, [51] [52] [53] that have generally led to lower than desired cure rates and none of which appear to be candidates for further development. The 10-day bismuth potassium citrate, amoxicillin, and levofloxacin regimen provided poor results (e.g. 78.7% ITT and 83.8% PP), but 14-day therapy achieved a good result (i.e. 94.6% PP and 87.5% ITT) [54] and speaks against the hypothesis that bismuth-amoxicillin dual therapy might be a successful regimen (Table 5) .
Discussion
In China, antimicrobial resistance is typically high and increasing. Resistance to clarithromycin and fluoroquinolones has reached levels such that probably neither should be used as anti-H. pylori therapy without previous confirmation of the presence of an infection with a susceptible strain (i.e. tailored therapy). Metronidazole resistance is also high, suggesting that in bismuthcontaining quadruple therapy, it should only be administered at full doses and for at least 10 and preferably for 14 days [13, 28, 39] . In contrast, resistance to tetracycline, furazolidone, and amoxicillin is generally rare to nonexistent, making them ideal as components of the optimum anti-H. pylori regimen.
Clinically, at least one optimum regimen and an alternate are needed to ensure that all or most patients will be cured with a maximum of two regimens [56] . All of the currently effective drugs are cheap and multicenter randomized-controlled trials are required to confirm the optimal regimens in terms of the doses, durations, frequency of administration, and administration in relation to meals, and then to compare regimens in terms of tolerability, cost, etc. For example, in the recent study with bismuth, tetracycline, metronidazole, and PPI quadruple therapy, B30% experienced side effects [39] . A comparison of this regimen with the Sardinian twice a day (with lunch and evening meals) would be of interest in terms of outcome and side effects [30] [31] [32] .
Although furazolidone is no longer available in many counties, and its use is associated with many side effects, especially in relation to interactions with foods and other drugs, it is an effective regimen drug for anti-H. pylori therapy [39, 57] and additional studies are required to identify the optimal use of this antimicrobial. A wellplanned development program, followed by optimization is needed to identify the best regimen(s) [58] .
Recommendations as to which regimens are best should specify all of the important details including drugs, doses, dosing intervals, dosing in relation to meals, formulation, number of administrations, and duration of therapy. A review of Table 1 clearly shows how what appears to be the same therapy may yield entirely different results when the actual regimen differs in terms of one or more of these components. As a general rule, 14-day regimens are to be preferred. The regimens offering the most promise for systematic development are shown in bold in Table 1 . These consist of 10-day or 14-day duration quadruple therapies containing bismuth, metronidazole, tetracycline, PPI or bismuth, furazolidone, and amoxicillin PP. Randomized multicenter trials are needed as well as pilot studies investigating modifications especially in relation to convenience and side effects (e.g. twice rather than three or four times daily or administration at the noon and evening meal instead of at breakfast and evening) that maintain effectiveness (i.e. treatment success Z 90% 
